secwatch / observer
8-K filed May 17, 2024, 7:59 PM ET ticker CTMX CIK 0001501989
other confidence high sentiment neutral materiality 0.40

Stockholders approve doubling authorized common stock to 300M shares

CytomX Therapeutics, Inc.

item 5.03item 5.07item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-24-141699
form_type
8-K
ticker
CTMX
cik
0001501989
company_name
CytomX Therapeutics, Inc.
filed_at
2024-05-17T23:59:59+00:00
discovered_at
2026-05-14T18:03:18.705232+00:00
generated_at
2026-06-01T15:24:34.044642+00:00
sec_items
["5.03", "5.07", "9.01"]
event_type
other
sentiment
neutral
materiality_score
0.4
calibrated_materiality_score
0.4
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-24-141699
json_url
https://secwatch.observer/filing/0001193125-24-141699.json
markdown_url
https://secwatch.observer/filing/0001193125-24-141699.md
text_url
https://secwatch.observer/filing/0001193125-24-141699.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/d816353d8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

cd71f4c4745645ec8a00e29463c09ace70e099c4

CytomX Therapeutics, Inc.: Increased authorized shares of common stock from 150,000,000 to 300,000,000 shares (effective 2024-05-17).

On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

4de2c3da2427848f5ae03ea278bfbf3f4eb886ff

CytomX Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.

Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723

SEC 8-K Item 5.07 confidence 0.98 SEC evidence

6560b6f50e1918a1913d47fae33dee7b4d160133

CytomX Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of common stock from 150,000,000 to 300,000,000 at the 2024-05-15 meeting.

Proposal 3. The Company’s stockholders approved of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares. FOR AGAINST ABSTAIN 42,707,436 3,211,496 999,741

SEC 8-K Item 5.07 confidence 0.98 SEC evidence

84007f2377ce107ffbc804776b397b63ec85e053

CytomX Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2024-05-15 meeting.

Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. FOR AGAINST ABSTAIN 46,522,474 369,346 26,853

SEC 8-K Item 5.07 confidence 0.98 SEC evidence

f7ae2ae9044b16d49ab9b3139103b88de15627f5

CytomX Therapeutics, Inc. shareholders approved Election of Class III directors at the 2024-05-15 meeting.

Proposal 1. The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Alan Ashworth, Ph.D., FRS 28,770,373 514,091 79,486 17,554,723 James R. Meyers 28,970,141 324,310 69,499 17,554,723 Halley Gilbert 24,008,423 5,271,685 83,842 17,554,723

SEC 8-K Item 5.07 confidence 0.95 SEC evidence

Comparable filings

BAX

Baxter shareholders approve charter amendment and incentive plan; board adopts new executive severance plan

BAXTER INTERNATIONAL INC May 8, 2026, 7:59 PM ET other Items 5.02, 5.07, 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 5.07, 9.01 same event type: other similar materiality

This filing

On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).

Comparable filing

the Board approved a corresponding amendment and restatement of the Company’s Amended and Restated Bylaws (the “Amended Bylaws”) reflecting that the number of directors on the Board shall not be less than seven nor more than twelve

Filing page SEC filing

KGS

Kodiak shareholders approve board declassification and supermajority removal

Kodiak Gas Services, Inc. May 7, 2026, 7:59 PM ET other Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 5.07, 9.01 same event type: other similar materiality

This filing

On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).

Comparable filing

At the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Kodiak Gas Services, Inc. (the “Company”) held on May 7, 2026, the Company’s shareholders approved certain amendments (the “Charter Amendments”) to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to (i) phase in declassification of the Board of Directors (the “Board”) and (ii) eliminate certain supermajority voting requirements and other obsolete provisions.

Filing page SEC filing

PSA

Shankh Mitra re-elected as chairman with 24% against votes; all proposals pass

Public Storage May 11, 2026, 7:59 PM ET other Items 5.07, 8.01

same fact type: shareholder_vote same SEC item: 5.07 same event type: other similar materiality

This filing

Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723

Comparable filing

3. The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 as follows: Votes For Votes Against Abstain Broker Non-Votes 153,317,363 10,957,104 59,863 —

Filing page SEC filing

XBP

XBP Global Holdings annual meeting elects directors, approves auditor and say-on-pay

XBP Global Holdings, Inc. June 1, 2026, 5:00 PM ET other Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other

This filing

Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723

Comparable filing

· Proposal 3 — To consider and vote upon a proposal to approve, on an advisory (non-binding) basis, the compensation of our named executive officers (the “say-on-pay vote”): Votes For Votes Against Votes Abstained Broker Non-Votes 8,208,462 1,323,885 1,011 577,920

Filing page SEC filing

SCHW

Charles Schwab files Certificate of Elimination for Series I Preferred Stock

SCHWAB CHARLES CORP June 1, 2026, 5:00 PM ET other Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other

This filing

On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).

Comparable filing

On June 1, 2026, The Charles Schwab Corporation (the “Company”) filed a Certificate of Elimination with the Secretary of State of the State of Delaware with respect to the Company’s 4.000% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series I (“Series I Preferred Stock”), which, effective upon filing, eliminated from the Company’s Fifth Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations for the Series I Preferred Stock.

Filing page SEC filing

AXON

Axon shareholders elect all 9 director nominees and approve say-on-pay at 2026 annual meeting

AXON ENTERPRISE, INC. June 1, 2026, 4:10 PM ET other Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other

This filing

Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723

Comparable filing

The non-binding advisory vote to approve the compensation of the Company's named executive officers was approved as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 54,903,698 6,239,017 112,972 11,665,236

Filing page SEC filing

NRGV

Energy Vault shareholders elect three Class II directors and ratify BDO USA as auditor

Energy Vault Holdings, Inc. June 1, 2026, 11:36 AM ET other Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other

This filing

Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723

Comparable filing

Proposal 2 - Ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026 Votes For Votes Against Votes Abstaining Broker Non-Votes 127,775,985 168,810 59,341 —

Filing page SEC filing

SCI

SCI shareholders approve board governance changes: director minimum cut to 3, board can fill vacancies

SERVICE CORP INTERNATIONAL May 8, 2026, 7:59 PM ET other Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other

This filing

On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).

Comparable filing

The amendments to the Articles of Incorporation, which became effective on May 7, 2026, and the amendments to the Bylaws, which became effective on May 6, 2026 , include (i) changes permitting the Board to increase the number of directors and fill newly created vacancies, thereby eliminating restrictions requiring that newly created directorships be filled only by shareholders at an annual or special meeting, and (ii) changes reducing the minimum number of directors constituting the Board from nine to three directors (with the maximum remaining at fifteen directors).

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-24-141699
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.